Physician profile
Mark C Dickmeyer
NPI 1457349201
$2,684.61
in general payments reported to CMS, 2019-2025
29 companies · $207 in 2025
The $207 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,026 · 2020: $156 · 2022: $294 · 2023: $556 · 2024: $446 · 2025: $207.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,209.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,208.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $447.20 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $366.21 | 2019-2025 | Vraylar, Ubrelvy |
| Pfizer INC. | $184.01 | 2019-2025 | |
| Axsome Therapeutics, INC. | $182.52 | 2023-2024 | Auvelity |
| Astrazeneca Pharmaceuticals Lp | $167.59 | 2019-2023 | Farxiga |
| Sanofi-Aventis U.S. LLC | $158.64 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $151.11 | 2019-2024 | Xifaxan |
| Lilly USA, LLC | $148.05 | 2019-2024 | Mounjaro, Zepbound |
| Amgen INC. | $117.46 | 2019-2025 | Repatha, Otezla, Evenity |
| Otsuka America Pharmaceutical, INC. | $77.61 | 2023-2025 | Rexulti |
| Astellas Pharma US INC | $76.29 | 2019-2024 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $62.42 | 2023-2024 | |
| Xeris Pharmaceuticals, INC. | $62.34 | 2022-2024 | Gvoke Hypopen |
| Teva Pharmaceuticals USA, INC. | $59.00 | 2019-2025 | Austedo Xr, Austedo Xr |
| Janssen Pharmaceuticals, INC | $56.97 | 2019-2023 | Spravato |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $55.57 | 2019-2020 | |
| Exact Sciences Corporation | $49.52 | 2024-2025 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $47.06 | 2019 | |
| Genentech USA, INC. | $31.16 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.80 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.07 | 2019-2023 | Trintellix |
| Antares Pharma, INC. | $23.39 | 2019-2022 | |
| Allergan, INC. | $17.79 | 2020 | |
| Sunovion Pharmaceuticals INC. | $15.79 | 2022 | |
| Abbott Laboratories | $15.62 | 2024 | Freestyle Libre 3 |
| Lundbeck LLC | $15.09 | 2025 | Rexulti |
| Mylan Specialty L.P. | $14.41 | 2023 | Yupelri |
| Shire North American Group INC | $12.92 | 2019 | |
| Ironwood Pharmaceuticals, INC | $11.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Dickmeyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.